Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.2.1.7 (
BAL
)
1,977
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MicroRNA signatures of
BAL
cells and alveolar macrophages are currently lacking in IPF. Here we sought to investigate the expression of fibrosis-related microRNAs in the cellular component of the
BAL
in IPF. We thus focused on microRNAs previously associated with fibrosis (miR-29a, miR-29b, miR-29c, let-7d, and miR-21) and rapid IPF progression (miR-185, miR-210, miR-302c-3p miR-376c and miR-423-5p). Among the tested microRNAs miR-29a and miR-185 were found significantly downregulated in IPF while miR-302c-3p and miR-376c were not expressed by
BAL
cells. Importantly, the downregulation of miR-29a inversely correlated with the significantly increased levels of
COL1A1
mRNA in IPF
BAL
cells. Collagen 1 a was found mainly overexpressed in alveolar macrophages and not other cell types of the
BAL
by immunofluorescence. In view of the downregulation of miR-185, we tested the response of THP-1 macrophages to profibrotic cytokine TGFb and observed the downregulation of miR-185. Conversely, proinflammatory stimulation lead to miR-185 upregulation. Upon examination of the mRNA levels of known miR-185 targets AKT1, DNMT1 and HMGA2, no significant correlations were observed in the
BAL
cells. However, increased levels of total AKT and AKTser473 phosphorylation were observed in the IPF
BAL
cells. Furthermore, miR-185 inhibition in THP-1 macrophages resulted in significant increase of AKTser473 phosphorylation. Our study highlights the importance of
BAL
microRNA signatures in IPF and identifies significant differences in miR-185/AKT and miR-29a/collagen axes in the
BAL
cells of IPF patients.
...
PMID:MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF BAL cells. 2776 60